Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Settles Provigil Pay-For-Delay Class Action; Will FTC Deal Follow?

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.

You may also be interested in...



Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements

Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.

Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?

California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.

Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?

California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS078395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel